

FAD ASINCRONA

REAZIONI CUTANEE IN CORSO DI TERAPIA ONCOLOGICA: COME RICONOSCERLE E CURARLE

FAD Task Force SIDeMaST TICURO

12 Gennaio 2026 – 12 Agosto 2026

Indirizzo fisico piattaforma:

Via Luigi Galvani 50 – Ozzano dell'Emilia (BO)

Indirizzo web:

fad.sidemast.org

DESTINATARI DELL'ATTIVITÀ FORMATIVA: L'evento è rivolto a Medici Chirurghi specializzati in: tutte le professioni.

OBIETTIVO FORMATIVO Epidemiologia - prevenzione e promozione della salute – diagnostica – tossicologia con acquisizione di nozioni tecnico-professionali.

ACQUISIZIONE COMPETENZE TECNICHE	IL PARTECIPANTE ACQUISIRÀ COMPETENZE TECNICO PROFESSIONALI IN TEMA DI REAZIONI CUTANEE IN PAZIENTI ONCOLOGICI
ACQUISIZIONE COMPETENZE DI PROCESSO	IL PARTECIPANTE ACQUISIRÀ COMPETENZE DI PROCESSO ATTRAVERSO UN INCONTRO FINALIZZATO AD UNA PIÙ EFFICACE ED AGGIORNATA GESTIONE DIAGNOSTICO-TERAPEUTICA DELLE PATOLOGIE TRATTATE.
ACQUISIZIONE COMPETENZE DI SISTEMA	IL PARTECIPANTE ACQUISIRÀ COMPETENZE DI SISTEMA APPRENDENDO AD UTILIZZARE IN MODO OTTIMALE LE RISORSE STRUMENTALI E TECNOLOGICHE NELL'APPLICAZIONE DI PERCORSI ASSISTENZIALI E DIAGNOSTICI CONDIVISI E BASATI SULL'EVIDENZA SCIENTIFICA

RAZIONALE

Le terapie oncologiche nel corso degli ultimi anni sono sempre più mirate ed efficaci. A fianco alle tradizionali chemioterapie, che hanno come bersaglio qualsiasi cellula ad alto ciclo replicativo, sono oggi disponibili farmaci a bersaglio molecolare (target therapy) che colpiscono selettivamente le cellule tumorali e farmaci immunoterapici (inibitori dei checkpoint immunitari) che sono in grado di rimuovere il blocco che il tumore mette al sistema immunitario, togliendo il freno all'attivazione dei linfociti T, aumentano l'immunità antitumorale dell'ospite.

È noto che la pelle è coinvolta nelle terapie oncologiche, sia come organo spia di efficacia del trattamento, ma anche e soprattutto, come organo bersaglio che manifesta effetti collaterali, a volte anche gravi. Le tossicità dei farmaci delle nuove classi terapeutiche e gli effetti collaterali sono diversi da quelli della chemioterapia tradizionale, perchè i nuovi farmaci hanno spesso come organo bersaglio la pelle provocando eruzioni cutanee, prurito, desquamazione, ulcere e ragadi, ma anche follicoliti e perionissi.

È necessaria la presa in carico continuativa del paziente anche da parte del dermatologo, che deve imparare a riconoscere e trattare correttamente gli effetti collaterali dei farmaci oncologici. È importante che questi disturbi vengano trattati precocemente per evitare che in alcuni pazienti, che hanno reazioni importanti, si debba essere costretti ad interrompere le cure oncologiche. Per questo è necessaria una stretta collaborazione fra oncologo e dermatologo per assicurare la migliore gestione del paziente, sia nel setting ospedaliero ma anche in quello ambulatoriale. Lo scopo della FAD è quella di formare e informare dermatologi ed oncologi al fine di avere una expertise specifica per la gestione e la prevenzione degli effetti collaterali da farmaci oncologici, in modo da poter migliorare la qualità di vita e la aderenza dei pazienti al trattamento.

PROGRAMMA SCIENTIFICO FAD

MODULO 1 tempo di consultazione 5 ore

Prevenzione cutanea in corso di terapia oncologica e reazioni avverse ai farmaci anti CDK4/6i – *Pietro Sollena* 40 min

Reazioni cutanee frequenti durante la chemioterapia – *Maria Carmela Annunziata* 40 min

Terapie target anti-EGFR e reazioni cutanee – *Maria Concetta Romano* 40 min

Reazioni cutanee in corso di terapia target con B-Raf e Mek inibitori – *Anna Elisa Verzi* 40 min

Eventi avversi cutanei in corso di immunoterapia – *Davide Fattore* 40 min

Paziente oncologico ed esposizione a radiazioni ultraviolette o a radiazioni terapeutiche: prevenzione e terapia degli effetti cutanei – *Alessia Pacifico* 40 min

Società Italiana di Dermatologia medica, chirurgica, estetica e di MST (già SIDEV)

www.sidemast.org

Farmaci oncologici ed effetti sugli annessi: focus su unghie e capelli – *Michela Starace* 40 min

Paziente oncologico e dermo-estetica: cosa fare e cosa non fare – *Elisabetta Fulgione* 40 min

MODULO 2 tempo di consultazione 12 ore

Table II. Sources accessed for analysis

All materials were downloaded August 24, 2014.

AAD, American Academy of Dermatology; AF, Arthritis Foundation; M, methotrexate; NBUVB, narrowband ultraviolet B; NPF, National

Psoriasis Foundation; Ps, Psoriasis; PsA, psoriatic arthritis.

*No source data available for analysis.

Drug Reactions Affecting Hair: Diagnosis

Antonella Tosti, MD*, Massimiliano Pazzaglia, MD

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

Michael Axelson¹, Ke Liu¹, Xiaoping Jiang², Kun He², Jian Wang³, Hong Zhao³, Dubravka Kufrin¹, Todd Palmby¹, Zedong Dong⁴, Anne Marie Russell⁴, Sarah Miksinski⁴, Patricia Keegan¹, and Richard Pazdur¹

Exclamation marks and other trichoscopic signs of chemotherapy-induced alopecia

Rodrigo Pirmez¹, Juan Piñeiro-Maceira² and Celso Tavares Sodr e¹

Hair shaft abnormalities after chemotherapy and tamoxifen therapy in patients with breast cancer evaluated by optical coherence tomography

J. Lindner,¹ K. Hillmann,² U. Blume-Peytavi,² J. Lademann,³ A. Lux,⁴ A. Stroux,⁵ A. Schneider⁶ and N. Garcia Bartels²

Infinity hair: a new trichoscopic finding for chemotherapy-induced alopecia

¹ Rossi A, Fortuna MC, Caro G et al. Monitoring chemotherapy-induced alopecia with trichoscopy. *J Cosmet Dermatol* 2019; 18:575–80.

² Anagen effluvium. In: *Atlas of Trichoscopy: Dermoscopy in Hair and Scalp Disease*. Rudnicka L, Olszewska M, Rakowska A (eds), 1st edn. London: Springer, 2012; 248.

Acknowledgement

M. George,¹ T. P. Afra,¹ P. Santhosh,¹

G. Nandakumar,¹ D. Balagopalan² and S. Sreedharan³

Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?

Tongyu C. Wikramanayake * , Nicole I. Haberland, Aysun Akhundlu, Andrea Laboy Nieves and Mariya Miteva Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA

Nail disorders in patients with chronic renal failure and undergoing haemodialysis treatment: a case-control study

P Dyachenko,*† A Monselise,† A Shustak,‡ M Ziv,† D Rozenman†

†Department of Dermatology and ‡Nephrology Unit, Ha'emek Medical Centre, Afula, 18101, Israel

Topical propranolol 1% cream for pyogenic granulomas of the nail: open-label study in 10 patients

D. Calista,1,* L. Riccioni,2 L. Bagli,3 F. Valenzano4

1Department of Dermatology, "M. Bufalini" Hospital, 2Pathology Unit, "M.

Bufalini" Hospital, 3Molecular Genetic Unit, Laboratorio Unico Area Vasta, Cesena, 4San Gallicano Dermatologic Institute, IRCCS, Rome, Italy

Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life

P.-H. Ho,1 I.-C. Lin,2 X. Yang,3 Y.-T. Cho,1 C.-Y. Chu1,*

1Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

2Department of Dermatology, National Cheng Kung University Hospital, Tainan, Taiwan

3Department of Pharmacology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan

Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study

Mark Hackbarth & Norbert Haas & Christina Fotopoulou & Werner Lichtenegger & Jalid Sehouli

Received: 6 February 2007 / Accepted: 11 July 2007 / Published online: 7 August 2007

Springer-Verlag 2007

Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management

Kristen K. Miller, MD,a Loren Gorcey, BA,a and Beth N. McLellan, MDb

New York and Bronx, New York

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Mario E. Lacouture & Milan J. Anadkat & René-Jean Bensadoun & Jane Bryce & Alexandre Chan &

Joel B. Epstein & Beth Eaby-Sandy & Barbara A. Murphy & MASCC Skin Toxicity Study Group

Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab

Bradford PT, Goldstein AM, McMaster ML, Tucker MA. *Acral*

lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. *Arch Dermatol.* 2009;145(4):427-434. <https://doi.org/10.1001/archdermatol.2008.6092>. Huang K, Fan J, Misra S. *Acral*

lentiginous melanoma: incidence and survival in the United States, 2006-2015, an analysis of the SEER registry. *J Surg Res.* 2020;251:329-339. <https://doi.org/10.1016/j.jss.2020.02.010> 3. Lee RJ, Madan RA, Kim J, Posadas EM, Yu EY.

Disparities in cancer care and the Asian American population. *Oncologist.*

2021;26(6):453-460. <https://doi.org/10.1002/onco.13748> 4. Fujisawa Y, Yoshikawa S, Minagawa A, et al.

Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. *Cancer Med.* 2019;8(5):

2146-2156. <https://doi.org/10.1002/cam4.2110>

5. Moore KJ, Hubbard AK, Williams LA, Spector LG. *Childhood*

Cancer incidence among specific Asian and Pacific Islander populations in the U.S. *Int J Cancer.*

2020;147(12):3339-3348.

<https://doi.org/10.1002/ijc.33153>

Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature

Pietro Sollena MD1,2, Maria Mannino MD1,2, Francesco Tassone MD1,2, Maria Alessandra Calegari MD3, Ettore D'Argento MD3, Ketty Peris MD1,2

1Istituto di Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy; 2Fondazione Policlinico

Universitario A. Gemelli - IRCCS, Rome, Italy; 3UOC Oncologia Medica, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy

Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions

Jonathan L. Curry1,2, MD, Carlos A. Torres-Cabala1,2, MD, Kevin B. Kim3, MD,

Michael T. Tetzlaff1,2, MD, PhD, Madeleine Duvic2, MD, Kenneth Y. Tsai2, MD, PhD,

David S. Hong4, MD, and Victor G. Prieto1,2, MD, PhD

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

Mario Lacouture¹ · Vincent Sibaud²

Published online: 30 October 2018

Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management

Athanasia Varvaresou PhD¹ | Kriton Iakovou PhD² | Fotini Mellou MS, PhD¹ |

Dimetrios Myrogiannis MD, PhD³ | Spyros Papageorgiou MS¹ Received: 17 December 2018

Cutaneous adverse effects of targeted therapies

Part I: Inhibitors of the cellular membrane

James B. Macdonald, MD,^{a,b} Brooke Macdonald, BA,^c Loren E. Golitz, MD,^{d,e}

Patricia LoRusso, DO,^f and Aleksandar Sekulic, MD, PhD^g

Provo, Utah; Aurora, Colorado; Detroit, Michigan; and Scottsdale, Arizona J AM ACAD DERMATOL

FEBRUARY 2015

Cutaneous adverse effects of targeted therapies

Part II: Inhibitors of intracellular molecular signaling pathways

James B. Macdonald, MD,^{a,b} Brooke Macdonald, BA,^c Loren E. Golitz, MD,^{d,e}

Patricia LoRusso, DO,^f and Aleksandar Sekulic, MD, PhD^g

Provo, Utah; Aurora, Colorado; Detroit, Michigan; and Scottsdale, Arizona J AM ACAD DERMATOL

FEBRUARY 2015

Dermatologic adverse events associated with targeted therapies for melanoma

Article · October 2021

DOI: 10.1080/14740338.2022.1986000

Accepted Manuscript

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review

Mario E. Lacouture, Milan Anadkat, Aminah Jatoi, Tamer Garawin, Chet Bohac, Edith

Mitchell

PII: S1533-0028(16)30278-X

DOI: 10.1016/j.clcc.2017.12.004

Reference: CLCC 420

Nail toxicities induced by systemic anticancer treatments

Caroline Robert*, Vincent Sibaud*, Christina Mateus, Michèle Verschoore, Cécile Charles, Emilie Lanoy,

Robert Baran Lancet Oncol 2015; 16: e181–89 Journal Pre-proof

Prevention and Management of Dermatological Toxicities Related to Anticancer

Agents: ESMO Clinical Practice Guidelines[†]

M.E. Lacouture, V. Sibaud, P.A. Gerber, C. van den Hurk, P. Fernández-Peñas, D.

Santini, F. Jahn, K. Jordan, on behalf of the ESMO Guidelines Committee

PII: S0923-7534(20)43157-6

DOI: <https://doi.org/10.1016/j.annonc.2020.11.005>

Reference: ANNONC 407

To appear in: Annals of Oncology

Received Date: 28 August 2020

European recommendations for management of immunecheckpoint inhibitors-derived dermatologic adverse events.

The EADV task force 'Dermatology for cancer patients' position statement

Z. Apalla,^{1,*} V. Nikolaou,² D. Fattore,³ G. Fabbrocini,³ A. Freites-Martinez,⁴ P. Sollena,^{5,6}

M. Lacouture,⁷ L. Kraehenbuehl,^{7,8,9} A. Stratigos,² K. Peris,^{5,6} E. Lazaridou,¹ B. Richert, J EADV 2022, 36, 332–350

Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study

Pietro Sollena ^{1,*},[†], Nikolaou Vasiliki ², Elias Kotteas ³, Alexander J. Stratigos ², Davide Fattore ⁴,

Armando Orlandi ⁵, Maria Mannino ⁶, Marcello Di Pumpo ⁷, Monika Fida ⁸, Michela Starace ⁹,

Zoe Apalla ¹⁰, Maria Concetta Romano ¹¹, Julia Riganti ¹², Sonia Segura ¹³, Azael Freites Martinez ¹⁴,

Gabriella Fabbrocini ⁴ Vincent Sibaud ¹⁵, Ketty Peris ^{1,6} and on behalf of the EADV Task Force

"Dermatology for Cancer Patients" Cancers 2023, 15, 3658

Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients*

Vasiliki A. Nikolaou iD ¹, Zoe Apalla iD ², Cristina Carrera iD ^{3,4,5}, Davide Fattore iD ⁶, Pietro Sollena,⁷

Julia Riganti,⁸ Sonia Segura,⁹ Azael Freites-Martinez,¹⁰ Konstantinos Lallas iD ¹¹, Maria Concetta

Romano,¹² Chrysa Oikonomou,¹³ Michela Starace iD ¹⁴, Meletios A. Dimopoulos,¹⁵ Athanassios Kyrgidis iD

¹⁶, Elizabeth Lazaridou iD ², Priscila Giavedoni iD ³, Maria Carmela Annunziata iD ⁶, Ketty Peris,^{7,17}

Maria Echeverría,⁸ Emilio Lopez-Tujillo,⁹ Konstantinos Syrigos,¹⁸ Chryssoula Papageorgiou iD ²,

Sebastian Podlipnik iD ^{3,4}, Gabriella Fabbrocini,⁶ Ana C. Torre,⁸ Christina Kemanetzi,² Lorena Villa-

Crespo,³ Aimilios Lallas iD ¹¹, Alexander J. Stratigos iD ¹ and Vincent Sibaud¹⁹ British Journal of

Dermatology (2022) 187, pp962–969

Breast Care 2023 May ; 18 (2) : 141-149

doi: 10.1159/000528280

Review Article a Multidisciplinary Evaluation for Advanced Supportive Care of Breast Cancer Patients .
Adelina Petronea Marta Carlesimo, b Maria Caterina Fortuna, b Fedro Alessandro Peccatori, cGiovanni
Codacci-Pisanelli, d Raffaele Barbara, e Sara Cruciani, f Pier Andrea Serra, g Laura Maioli, h Margherita
Maioli, f ,*and Gloria Trocchi i

J Am Acad Dermatol. 2021 Sep; 85(3): 693–707.

doi: 10.1016/j.jaad.2020.08.005

Restorative Oncodermatology: Diagnosis and Management of Dermatologic Sequelae from Cancer
Therapies

Anthony M. Rossi, MD1,2, Brian P. Hibler, MD1,2, Cristian Navarrete-Dechent, MD3, Mario E. Lacouture,
MD1,2

J Cosmet Dermatol 2020 Apr;19(4):782-788. doi: 10.1111/jocd.13211. Epub 2019 Nov 26.

DOI: 10.1111/jocd.13211

Target therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management
Varvaresou PhD1 | Kriton Iakovou PhD2 | Fotini Mellou MS, PhD1 | Dimetrios Myrogiannis MD, PhD3 |
Spyros Papageorgiou MS

Cancer Manag Res. 2020; 12: 9363–9374.

doi: 10.2147/CMAR.S220976

Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management

Rossana Berardi,1 Francesca Morgese,1 Silvia Rinaldi,1 Mariangela Torniai,1 Giulia Mentrasti,1 Laura
Scortichini,1 and Riccardo Giampieri1

Aesthetic Treatments in Cancer Patients

Clin Cosmet Investig Dermatol. 2021 Dec 4:14:1831-1837.

doi: 10.2147/CCID.S342734.

Ilaria Proietti, Nevena Skroza, Alessandra Mambrin, Federica Marraffa, Ersilia Tolino, Nicoletta Bernardini
Anna Marchesiello, Giovanni Rossi, Salvatore Volpe, Concetta Potenza.

Qual Life Res. 2019; 28(6): 1543–1553.

doi: 10.1007/s11136-019-02133-9

A pilot study on aesthetic treatments performed by qualified aesthetic practitioners: efficacy on health-
related quality of life in breast cancer patients

Serena Oliveri1,2 · Flavia Faccio1,2 · Silvia Pizzoli1,2 · Dario Monzani1 · Carolina Redaelli3 · Mirella Indino3 ·
Gabriella Pravettoni1,2

Cancer Manag Res 2013; 5: 401-408

doi:10.2147/CMAR.S52256

Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel

René-Jean Bensadoun,¹ Phillipe Humbert,² Jean Krutman,³ Thomas Luger,⁴ Raoul Triller,⁵ André Rougier,⁶ Sophie Seite,⁶ and Brigitte Dreno⁷

European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement. Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, Lacouture M, Kraehenbuehl L, Stratigos A, Peris K, Lazaridou E, Richert B, Vigiarios E, Riganti J, Baroudjian B, Filoni A, Dodiuk-Gad R, Lebbé C, Sibaud V.. *J Eur Acad Dermatol Venereol.* 2022 Mar;³⁶(3):332-350. doi: 10.1111/jdv.17855. Epub 2021 Dec 15. PMID: 34910332.

Autoimmune Skin Diseases and Immune Checkpoint Inhibitors Fattore D, Potestio L, Genco L, Pages C, Ortiz A, Fabbrocini G, Sibaud V.. *Crit Rev Immunol.* 2022;⁴²(3):11-22. doi: 10.1615/CritRevImmunol.2023047032. PMID: 37017623.

Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients. Nikolaou VA, Apalla Z, Carrera C, Fattore D, Sollena P, Riganti J, Segura S, Freites-Martinez A, Lallas K, Romano MC, Oikonomou C, Starace M, Dimopoulos MA, Kyrgidis A, Lazaridou E, Giavedoni P, Annunziata MC, Peris K, Echeverría M, Lopez-Tujillo E, Syrigos K, Papageorgiou C, Podlipnik S, Fabbrocini G, Torre AC, Kemanetzi C, Villa-Crespo L, Lallas A, Stratigos AJ, Sibaud V.. *Br J Dermatol.* 2022 Dec;¹⁸⁷(6):962-969. doi: 10.1111/bjd.21781. Epub 2022 Sep 6. PMID: 35861701.

Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study. Freites-Martinez A, Nikolaou V, Lallas K, Carrera C, Sollena P, Apalla Z, Starace M, Fattore D, Fabbrocini G, Segura S, Riganti J, Sibaud V. *J Am Acad Dermatol.* 2023 Mar;⁸⁸(3):718-720. doi: 10.1016/j.jaad.2022.08.063. Epub 2022 Sep 22. PMID: 36152697.

Scleroderma-like Syndrome in the Setting of Pembrolizumab Therapy for Non-Small Cell Lung Cancer: Diagnosis and Dermatologic Management. Fattore D, Battista T, De Lucia M, Annunziata MC, Fabbrocini G. *Case Rep Dermatol.* 2022 Aug ¹⁹;14(2):225-229. doi: 10.1159/000525887. PMID: 36158854; PMCID: PMC9459594.

Atezolizumab-Induced Acrodermatitis and Pustular Psoriasis in a Patient with Non-Small Cell Lung Cancer: A Rare Case Report. Fattore D, Esposito G, Carangelo L, Luciano MA, Megna M.. Case Rep Dermatol. 2024 Feb 21;16(1):42-46. doi: 10.1159/000535168. PMID: 38384677; PMCID: PMC10881193.

“Il Corpo Ritrovato”: Dermocosmetological Skin Care Project for the Oncologic Patient

G. Fabbrocini,¹ M. C. Romano,² N. Cameli,³ M. Mariano,¹ F. Pastore,¹ M. C. Annunziata,¹ C. Mazzella,¹ Valerio De Vita,¹ Maria Chiara Mauriello,¹ and G. Monfrecola¹

¹Division of Clinical Dermatology, Department of Systematic Pathology, University of Naples Federico II, Street Sergio Pansini 5, Naples 80133, Italy


²ASL ROMA C and Division of Clinical Dermatology, University of Rome “Tor Vergata”, 00133 Rome, Italy

³Surgery of Aesthetic Dermatology of San Gallicano Dermatological Institute (IRCCS), 00118 Rome, Italy

Correspondence should be addressed to G. Fabbrocini, prenotazionebiennale@yahoo.it

Received 2 February 2011; Accepted 15 March 2011

Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients

First published: 21 July 2022 | <https://doi.org/10.1111/bjd.21781> | Citations: 2 Plain language summary available online Vasiliki A. Nikolaou , Zoe Apalla, Cristina Carrera, Davide Fattore, Pietro Sollena, Julia Riganti, Sonia Segura, Azael Freitas-Martinez, Konstantinos Lallas, Maria Concetta Romano

Into the redox control: N-acetyl-cysteine pleiotropic effects from the laboratory to clinical applications

Tiziana Parasassia,^{*} Roberto Brunelli^b, Ewa K. Krasnowska^a, Thomas Lundeberg^c, Eugenia Pittalugaa, Maria Concetta Romano

^aDa Institute of Translational Pharmacology, CNR, Via del Fosso del Cavaliere 100, 00133 Roma, Italy

^bDepartment of Gynecologic-Obstetric and Urologic Sciences, Università di Roma Sapienza, Viale del

Policlinico 155, 00161 Roma, Italy ^cFoundation for Acupuncture and Alternative Biological Treatment

Methods, Sabbatsbergs Hospital, Olivecronas väg 1, 113 24 Stockholm, Sweden ^dDepartment of

Dermatology, Università di Roma Tor Vergata, Viale Oxford 81, 00133 Roma, Italy

“Il Corpo Ritrovato”: Dermocosmetological Skin Care Project for the Oncologic Patient

G. Fabbrocini, M. C. Romano, N. Cameli, M. Mariano, F. Pastore, M. C. Annunziata, C. Mazzella, Valerio De Vita, Maria Chiara Mauriello, and G. Monfrecola Division of Clinical Dermatology, Department of Systematic Pathology, University of Naples Federico II, Street Sergio Pansini 5, Naples 80133, Italy

ASL ROMA C and Division of Clinical Dermatology, University of Rome “Tor Vergata”, 00133 Rome, Italy

Surgery of Aesthetic Dermatology of San Gallicano Dermatological Institute (IRCCS), 00118 Rome, Italy

^{*}G. Fabbrocini: Email: prenotazionebiennale@yahoo.it Academic Editor: A. Sella ISRN Oncol. 2011; 2011: 650482.

Published online 2011 Apr 27. Doi

Acne-Like Rash in Cancer Patients

EADV Informat I O N Leaflet Fo R Pat I E N T S I Acne Publication date 2022 PRODUCED BY THE EADV
DERMATOLOGY FOR CANCER PATIENTS TASK FORCE

Prophylactic Dermatologic Treatment of Afatinib-Induced <skin Toxicities with Metastatic Lung Cancer: a pilot study

Maria Pia Fuggetta¹, Maria Rita Migliorino², Serena Ricciardi², Giorgia Osman², Daniela Iacono², Alvaro Leone³, Alessandra Lombardi², Giampietro Ravagnan¹, Stefania Greco², Daniele Remotti³, Maria Concetta Pucci Romano⁴ ¹Institute of Translational Pharmacology, CNR Rome Italy; ²UOSD of Oncologic Pneumology S. Camillo Forlanini Hospital, Rome, Italy; ³UOC of Anatomopathology, S. Camillo Forlanini Hospital, Rome Italy; ⁴UOSD of Dermatology S. Camillo Forlanini Hospital, Rome. January, 2019

Molecules in cancer immunotherapy: benefits and side effects.

Bateman AC. J Clin Pathol 2019; 72: 20-24

Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair and nails.

Lacouture M, Sibaud V. Am J Clin Dermatol 2018; 19 (Suppl 1): S 31- S 39

Evaluation of phototoxicity induced by the anticancer drug rucaparib: Scientific Reports

2022; 12: 3434

Vandetanib photoinduced cutaneous toxicities.

Doan HQ, Hu MI, Goldstein J, Piha-Paul SA, Subbiah V, Patel AB. Cutis 2019; 103 (5): E24-E29

Phototoxicity of B-RAF inhibitors: exclusively due to UVA radiation and rapidly regressive.

Gabeff R, Dutartre H, Khammari A, Boisrobert A, Quereux G, Brocard A, Saint-Jean M, Peuvrel L, Dreno B. Eur J Dermatol 2015; 25: 452-6

Photosensitivity and cancer immune targeted therapies. Photodermatol

Photoimmunol Photomed 2020; 36: 172-8

Luigia Panariello, Marianna Donnarumma, Rosario Vincenzo Iaffaioli, Paolo Chiodini, Maria Carmela Annunziata, Tiziana Peduto, Gabriella Fabbrocini **Skin Toxicities During Colorectal Cancer Chemotherapy: Incidence and Pearls of Treatment in Our Experience**. Clin Colorectal Cancer 2020 Dec;19(4):e235-e242. doi: 10.1016/j.clcc.2020.05.006. Epub 2020 May 29.

G Fabbrocini M C Annunziata, M Donnarumma. S Cacciapuoti C Marasca , A Tosti **Photodynamic therapy for periungual pyogenic granuloma-like during chemotherapy: our preliminary results.** **Support Care Cancer** 2018 May;26(5):1353-1355. doi: 10.1007/s00520-018-4056-x. Epub 2018 Feb 10.

Maria C Annunziata, Maria Vastarella, Claudio Marasca, Luigia Panariello, Marianna Donnarumma, Gabriella Fabbrocini. **Chemotherapy-induced periungual pyogenic granuloma: epidemiology and recurrence rates in our experience** *Ital J Dermatol Venerol.* 2022 Apr;157(2):198-199. doi: 10.23736/S2784-8671.18.06128-X. Epub 2018 Oct 11.

Maria Carmela Annunziata, Alfonso De Stefano, Gabriella Fabbrocini, Silvana Leo, Paolo Marchetti, Maria Concetta Romano, Ivana Romano Current **Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer** *Clin Drug Investig* 2019 Sep;39(9):825-834. doi: 10.1007/s40261-019-00811-7.

Yevgeniy Balagula, Claus Garbe, Patricia L Myskowski, Axel Hauschild, Bernardo L Rapoport, Christine B Boers-Doets, Mario E Lacouture. **Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors** . *Int J Dermatol* 2011 Feb;50(2):129-46. doi: 10.1111/j.1365-4632.2010.04791

Tempo di approfondimento 3 ore

Durata totale del programma formativo = 20 ore

RESPONSABILE SCIENTIFICO

Dott. **Pietro Sollena**, Medico Chirurgo specializzato in Dermatologia e venereologia, Dermatologo specialista presso la Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma

Elenco Relatori

NOME	QUALIFICA PROFESSIONALE	AFFILIAZIONE	LAUREA	QUALIFICA SCIENTIFICA
Annunziata Maria Carmela	Dirigente Medico	Dirigente Medico AOU Federico II, Napoli	Medicina e chirurgia	Dermatologia e Venereologia

Fattore Davide	Dirigente Medico	Dirigente Medico A.O.U. Policlinico Federico II Di Napoli	Medicina chirurgia	e	Dermatologia Venereologia	e
Fulgione Elisabetta	Specialista	Specialista presso UOC Dermatologia Università della Campania, Luigi Vanvitelli, Napoli	Medicina chirurgia	e	Dermatologia Venereologia	e
Pacifico Alessia	Dirigente Medico	Dirigente Medico Istituto Dermatologico San Gallicano, IFO, IRCCS	Medicina chirurgia	e	Dermatologia venereologia	e
Romano Maria Concetta	Professore	Professore Università Cattolica Sacro Cuore Roma	Medicina chirurgia	e	Dermatologia venereologia	e
Sollena Pietro	Specialista	Specialista presso Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma	Medicina chirurgia	e	Dermatologia venereologia	e
Starace Michela	Ricercatore	Ricercatore Dipartimento Di Scienze Mediche E Chirurgiche - Università degli studi di Bologna	Medicina chirurgia	e	Dermatologia venereologia	e
Verzì Anna Elisa	Ricercatore	Ricercatore Clinica Dermatologica, Università di Catania	Medicina chirurgia	e	Dermatologia venereologia a	e